Literature DB >> 17180149

Drug insight: aspirin resistance--fact or fashion?

Carlo Patrono1, Bianca Rocca.   

Abstract

The term aspirin resistance has been used increasingly in clinical studies. The aim of this Review is to analyze the origin of this term, to discuss the biochemical, functional and clinical correlates of the phenomenon and to offer a conceptual framework to redefine the major determinants of variability between individuals in response to aspirin. Awareness needs to be increased of factors that might interfere with the desired antiplatelet effect of aspirin, particularly in terms of patients' adherence to treatment and avoidable drug interactions with some traditional NSAIDs. Gaining such knowledge could result in improved care of patients and might avoid the requesting of unnecessary platelet function tests of unproven clinical significance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17180149     DOI: 10.1038/ncpcardio0728

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  27 in total

1.  Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome.

Authors:  Vivian K Kawai; Ingrid Avalos; Annette Oeser; John A Oates; Ginger L Milne; Joseph F Solus; Cecilia P Chung; C Michael Stein
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

2.  Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery.

Authors:  Tyler J Gluckman; Rhondalyn C McLean; Steven P Schulman; Thomas S Kickler; Edward P Shapiro; John V Conte; Kathleen W McNicholas; Jodi B Segal; Jeffrey J Rade
Journal:  J Am Coll Cardiol       Date:  2011-03-01       Impact factor: 24.094

3.  Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance.

Authors:  Giulia Renda; Maria Zurro; Gelsomina Malatesta; Benedetta Ruggieri; Raffaele De Caterina
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

4.  Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.

Authors:  Deepak Voora; Thomas L Ortel; Joseph E Lucas; Jen-Tsan Chi; Richard C Becker; Geoffrey S Ginsburg
Journal:  J Thromb Thrombolysis       Date:  2012-04       Impact factor: 2.300

5.  Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood.

Authors:  Gang Zhou; Gopal K Marathe; Belinda Willard; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2011-08-15       Impact factor: 5.157

6.  Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1.

Authors:  Wen Liu; Elizabeth M Poole; Cornelia M Ulrich; Richard J Kulmacz
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

Review 7.  Risk assessment and aspirin use in Asian and Western populations.

Authors:  Runlin Gao; Xiaoying Li
Journal:  Vasc Health Risk Manag       Date:  2010-10-21

8.  Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2).

Authors:  Gang Zhou; Gopal K Marathe; Jaana Hartiala; Stanley L Hazen; Hooman Allayee; W H Wilson Tang; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2013-03-18       Impact factor: 5.157

9.  Lipopolysaccharide is a direct agonist for platelet RNA splicing.

Authors:  Pavel N Shashkin; G Thomas Brown; Arundhati Ghosh; Gopal K Marathe; Thomas M McIntyre
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

10.  Effect of remote ischaemic conditioning on platelet aggregation and platelet turnover.

Authors:  Nina Rise; Jacobina Kristiansen; Anne-Mette Hvas; Erik L Grove; Morten Würtz; Søs Neergaard-Petersen; Steen Dalby Kristensen
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.